DISEASE-SPECIFIC CANCER CONTROL
CANCER CONTROL 2014 97
References
1. UNAIDS 2012. Global AIDS Response Progress Report. 2012. Zimbabwe Country
Report. Available at: http://www.unaids.org/en/dataanalysis/knowyourresponse/
countryprogressreports/2012countries/ce_ZW_Narrative_report.pdf.
2. Baeten JM, Chohan BH, Lavreys L et al. Correlates of human herpesvirus 8
seropositivity among heterosexual men in Kenya. AIDS 2002; 16:2073-8. PMID:
12370507
3. Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, and Biggar RJ. Transmission of human
herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS 2002; 16:2473-8.
PMID: 12461423
4. Lavreys L, Chohan B, Ashley R et al. Human herpesvirus 8: Seroprevalence and
correlates in prostitutes in Mombasa, Kenya. J Infect Dis 2003; 187:359-63. PMID:
12552419
5. Klaskala W, Brayfield BP, Kankasa C et al. Epidemiological characteristics of human
herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol
2007; 75:93-100. PMID: 15543582
6. Olsen SJ, Chang Y, Moore PS, Biggar RJ, and Melbye M. Increasing Kaposi's sarcomaassociated herpesvirus seroprevalence
with age in a highly Kaposi's sarcoma endemic
region, Zambia in 1985. AIDS 1998; 12:1921-5. PMID: 9792393
7. Newton R, Ziegler J, Bourboulia D et al. The seroepidemiology of Kaposi's sarcomaassociated herpesvirus (KSHV/HHV-8)
in adults with cancer in Uganda. Int J Cancer
2003; 103:226-32.
8. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS
in the United States 1980 - 2002. AIDS 2006;20:1645-54. PMID 16868446
9. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults
accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;
22:1897-908. PMID: 18784453
10.zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk
factors for high early mortality in patients on antiretroviral treatment in a rural district
of Malawi. AIDS 2006; 20:2355-2360. PMID: 17117022
11.castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Causespecific mortality and the contribution of immune reconstitution inflammatory
syndrome in the first 3 years after antiretroviral therapy initiation in an urban African
cohort. Clin Infect Dis. 2009; 49:965-72. PMID: 19673615
12.http://www.unaids.org/globalreport/global_report.htm
13.campbell TB, Borok M, Ndemera B, Fiorillo S, White IE, Zhang XQ, Machekano R,
Katzenstein D, Gwanzura L. Lack of Evidence for Frequent Heterosexual Transmission
of Human Herpesvirus 8 (HHV-8) in Zimbabwe. Clin Infect Dis 2009;48:1601-8.
PMCID: PMC2720069
14.chokunonga E, Levy LM, Bassett MT, Borok MZ, Mauchaza BG, Chirenje ZM, Parkin
DM, AIDS and cancer in Africa: The evolving epidemic in Zimbabwe. AIDS 1999;
13:2583-2588. PMID 10630528
15.gondos A, Chokunonga E, Brenner H, Parkin DM, Sankila R, Borok M, Chirenje ZM,
Nyakabau AM, Bassett MT. Cancer Survival in a Southern African Urban Population.
Int J Cancer 2004;112:860-864. PMID 15386382
16.boffi El Amari, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I,
Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel
B, the Swiss HIV Cohort Study. Predicting the evolution of Kaposi sarcoma, in the
highly active antiretroviral era. AIDS 2008; 22:1019-28. PMID: 18520345
17.martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, Eulalio Valencia
M, Alegre M, Podzamczer, D., Gonzalez-Lahoz J, and the Caelyx/KS Spanish Study
Group. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy
versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
AIDS 2004; 18:1737-40. PMID: 15280789
18.lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K,
Mauss S, Rockstroh JK, German Clinical AIDS Working Group. Treatment of HIV-1-
associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART
simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection
2004; 33:140-147. PMID: 15940415
19.cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized doubleblind study of pegylated liposomal doxorubicin
for the treatment of AIDS-related
Kaposi's sarcoma. Oncologist 2007; 12:114-23. PMID: 17227906
20.nguyen HQ, Magaret AS, Kitahat MM, Van Rompaey SE, Wald A, Casper C. Persistent
Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the
predictors of clinical response. AIDS 2008; 22:937-45. PMCID: PMC2730951
21.martin-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobi F,
Alegre M, Goyenechea A, Pedreira J, Gonzalez del Castillo J, Martinez- Lacasa J,
Ocampo A, Alsina M, Santos J, Podzamczer D, Gonzalez-Lahoz J, Caelyx/Kaposi's
Sarcoma Spanish Group. Long-term prognosis of HIV-infected patients with Kaposi
sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47:410-
417. PMID: 18582203
22.borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Watson H, Gwanzura L,
Schooley RT, Campbell TB. Evaluation of plasma human Herpesvirus 8 DNA as a
marker of clinical outcomes during antiretroviral therapy of AIDS-related Kaposi
sarcoma in Zimbabwe. Clin Infect Dis. 2010; 51:342-349. PMID: 20572760
23.M. Borok, unpublished data
24.makombe SD, Harries AD, Yu JK-L, Hochgesang M, Mhango E, Weigel R, Pasulani O,
Fitzgerald M, Schouten EJ, Libamba E. Outcomes of patients with Kaposi sarcoma who
start antiretroviral therapy under routine programme conditions in Malawi. Tropical
Doctor. 2008; 385-7. PMID: 18302849
25.nelson BC, Borok MB, Makadzange T, Mhlanga T, Campbell TB. AIDS-related Kaposi
sarcoma: Outcomes after initiation of highly active antiretroviral therapy under
routine conditions in Zimbabwe. International Conference on AIDS Malignancies and
Opportunistic Infections. Bethesda, 2010.
26.http://www.who.int/cancer/palliative/definition/en/
27.peter A. Selwyn, Mimi Rivard. Palliative Care for AIDS: Challenges and Opportunities
in the Era of Highly Active Anti-Retroviral Therapy. Journal of Palliative Medicine. June
2003, 6(3): 475-487. PMID: 14509497
28.sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: The World Health
Organization's Global Perspective. Vol. 24 No. 2 August 2002 J Pain and Symptom
Manage. PMID: 12231124
29.brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC
Medical Research Methodology 2006; 6:54 doi:10.1186/1471-2288-6-54. PMID:
17092344
30.borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Watson H, Gwanzura L,
Schooley RT, Campbell TB. Evaluation of plasma human Herpesvirus 8 DNA as a
marker of clinical outcomes during antiretroviral therapy of AIDS-related Kaposi
sarcoma in Zimbabwe. Clin Infect Dis 2010; 51:342-349. PMID: 20572760
and clinical research in the epidemiology and treatment of AIDSKS. She and Dr Campbell are
currently collaborating in two
randomized clinical trials, funded by NIAID and NCI through the
AIDS Clinical Trials Group and the AIDS Malignancy Consortium.
Dr Thomas Campbell has significant experience in clinical and
translational investigation of HIV/AIDS and AIDS-KS in African
settings that are highly relevant to the aims of this project.
Dr James Hakim, FRCP is an internist and clinical epidemiologist
with broad exposure to a wide spectrum of communicable and non-communicable diseases seen in sub-Saharan Africa.
Dr Jean Kutner is an experienced clinician/geriatrician. She is an
innovative researcher in the field of palliative care.
Dr Samantha MaWhinney, ScD is Professor of statistics and
currently Programme Director of the Department of Biostatistics
and Informatics in the Colorado School of Public Health.
Dr Eric Simoes has a broad background in infectious diseases with
specific training and expertise in epidemiology, and development
and assessment of WHO guidelines.